Therefore, FGF23 antagonists are strong candidates for the treatment of renal anemia, iron deficiency and associated inflammation, and have the potential to attenuate Klotho deficiency. The gene discussed is KL; the disease is hyperinsulinemic hypoglycemia, familial, 4.